[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334333-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334333-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","extended-hpv-genotyping-by-the-bd-onclarity-assay-concordance-with-screening-hpv-dna-assays-triage-biomarkers-and-histopathology-in-women-from-the-ntcc2-study","Extended HPV genotyping by the BD Onclarity assay - concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study","","Clinically validated human papillomavirus (HPV) assays are recommended for cervical cancer screening, and extended genotyping is increasingly explored as a triage biomarker reflecting differing oncogenic risks among high-risk HPV genotypes. Results of the BD Onclarity HPV assay were compared using residual baseline cervico-vaginal specimens from the NTCC2 trial versus screening HPV-DNA assays, cytology, p16/ki67, and E6/E7 mRNA triage. Concordance was substantial, highest in high-grade cytology, CIN3, and p16/ki67 or mRNA positivity, supporting good clinical performance across tests.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/extended-hpv-genotyping-by-the-bd-onclarity-assay-concordance-with-screening-hpv-dna-assays-triage-biomarkers-and-histopathology-in-women-from-the-ntcc2-study/334333/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/extended-hpv-genotyping-by-the-bd-onclarity-assay-concordance-with-screening-hpv-dna-assays-triage-biomarkers-and-histopathology-in-women-from-the-ntcc2-study/334333.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the aim of comparing the BD Onclarity assay with other screening tests?","Question",{"text":63,"@type":64},"To evaluate concordance between BD Onclarity HPV extended genotyping and screening HPV-DNA assays, and to relate results to triage biomarkers and histopathology using NTCC2 baseline specimens.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did BD Onclarity positivity relate to cytology severity and confirmed CIN3?",{"text":68,"@type":64},"Among baseline-positive cases, BD positivity increased with cytology severity, reaching 95.1% in ASC-H+ samples, and 96.9% among histologically confirmed CIN3.",{"name":70,"@type":61,"acceptedAnswer":71},"Which triage biomarkers showed high agreement with BD positivity?",{"text":72,"@type":64},"High-grade triage signals were associated with higher BD positivity: p16/ki67 dual staining positivity showed 90.9% among positive versus 69.6% among negative specimens, and E6/E7 mRNA positivity showed 93.4% in mRNA-positive cases versus 39.7% in mRNA-negative cases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334333,1791162591,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","| Clinical Microbiology | Research Article  \nExtended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study  \nLaura De Marco,1,2 Simonetta Bisanzi,3 Guglielmo Ronco,4 Pamela Mancuso,5 Francesca Carozzi,3 Elena Allia,1 Raffaella Rizzolo,4 Daniela Gustinucci,6 Helena Frayle,7 Jessica Viti,3 Anna Iossa,3 Elena Cesarini,6 Simonetta Bulletti,6 Basilio Passamonti,6 Silvia Gori,7 Laura Toniolo,8 Francesco Venturelli,5 Annarosa Del Mistro,7 Paolo Giorgi Rossi,5 Maria Benevolo,9 NTCC2 Working Group  \nAUTHOR AFFILIATIONS See affiliation list on p. 14.  \nABSTRACT The use of clinically validated human papillomavirus (HPV) assays is recommended in cervical cancer screening, and extended genotyping is getting attention as a triage biomarker because of the different oncogenic risk of the high-risk HPV genotypes. We compared the results of the Becton & Dickinson (BD) Onclarity HPV assay, on the residual baseline cervico-vaginal specimens of the NTCC2 trial, to those of the screening HPV-DNA assay (Cobas 4800 or HC2) and to cytology, p16/ki67 and E6/E7 mRNA triage results. We genotyped virtually all HPV-positive women and a consecutive sample of HPV-negatives. Among the 3,129 baseline-positives, 75.5%(k = 0.368) were BD-positive, as were 5 of the 333 baseline-negatives (1.5%) . The concordance between BD and HPV-DNA screening test was 87% for Cobas (1,250/1,436) and 65.9% for HC2 (1,115/1,693) . A higher than the recommended positivity threshold for Onclarity would increase the agreement but would not improve concordance in the overall screening population. Among the baseline-positive cases, we observed an increasing trend of BD positivity with cytology severity (from 71.6% in negative for intraepithelial lesion of malignancy to 95.1% in ASC-H+ samples), with histologically confirmed CIN3 (96.9%), with p16/ki67 dual staining positivity (90.9% among the positive and 69.6% among the negative specimens), and with E6/E7 mRNA positivity (93.4% in the mRNA-positive cases vs 39.7% among the mRNA-negatives) . Our findings confirm some disagreement among different HPV assays used for screening. Nevertheless, the agreement is substantial for women with high-grade cytology, histologically confirmed CIN3, and p16/ki67 or mRNA positivity at triage, thus confirming a good clinical performance of all the tests used.  \nCLINICAL TRIALS The NTCC2 trial is registered as [Clinicaltrials.gov](Clinicaltrials.gov) identifier NCT01837693 .  \nIMPORTANCE Large randomized clinical trials have demonstrated that human papillomavirus (HPV) testing for high-risk types is more effective than cytology in detecting pre-cancerous lesions and preventing cervical cancer. Its use is being implemented in cervical cancer screening in several countries. The most recent guidelines recommend a risk-based management. It is therefore important to assess the individual risk of having/developing high-grade lesions of women testing high-risk HPV-positive. A crucial viral factor influencing the risk is the HPV genotype since different types are associated to different carcinogenetic risks. Understanding the degree of concordance among different assays targeting either HPV presence/type(s) or cellular morphology and proteins’ expression provides knowledge useful to better define how these tests can be used in screening protocols for an effective triage and to anticipate the possible implementation issues. Our study shows that the concordance between tests is  \nEditor Day-Yu Chao, National Chung Hsing University, Taichung, Taiwan  \nAddress correspondence to Annarosa Del Mistro, [annarosa.delmistro@iov.veneto.it](annarosa.delmistro@iov.veneto.it).  \nPaolo Giorgi Rossi and Maria Benevolo contributed equally to this article.  \nM. B. and P. G. R., as principal investigator and former PI of the NTCC2 study, report nonfinancial support from Roche Diagnostics and Hologic S. r. l., which provided part of","cbCaicJ591oH3k5j","https://ap.wps.com/l/cbCaicJ591oH3k5j","pdf",1072833,16,"English","# Abstract\n# Clinical trials\n# Importance\n# Keywords","[{\"question\":\"What was the aim of comparing the BD Onclarity assay with other screening tests?\",\"answer\":\"To evaluate concordance between BD Onclarity HPV extended genotyping and screening HPV-DNA assays, and to relate results to triage biomarkers and histopathology using NTCC2 baseline specimens.\"},{\"question\":\"How did BD Onclarity positivity relate to cytology severity and confirmed CIN3?\",\"answer\":\"Among baseline-positive cases, BD positivity increased with cytology severity, reaching 95.1% in ASC-H+ samples, and 96.9% among histologically confirmed CIN3.\"},{\"question\":\"Which triage biomarkers showed high agreement with BD positivity?\",\"answer\":\"High-grade triage signals were associated with higher BD positivity: p16/ki67 dual staining positivity showed 90.9% among positive versus 69.6% among negative specimens, and E6/E7 mRNA positivity showed 93.4% in mRNA-positive cases versus 39.7% in mRNA-negative cases.\"}]","Extended HPV genotyping by the BD Onclarity assay - concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study | PDF",1790006288]